Based on these findings, we propose DUOX as a promising antagonistic, pleiotropic target in the treatment of human gut inflammation and IBD, which should be pursued by the generation of genetically engineered mouse models with conditional overexpression of DUOX2. The gene discussed is DUOX1; the disease is inflammatory bowel disease.